Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Vaccine ; 18(25): 2895-901, 2000 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-10812233

RESUMEN

Widespread use of conjugate vaccines against Streptococcus pneumoniae, by reducing carriage of S. pneumoniae serotypes included in the vaccine, may result in an increase in nasopharyngeal carriage of - and disease from - nonvaccine serotypes of the same species. Mathematical models predict that the extent of such replacement will depend positively on the degree to which carriage of vaccine-type S. pneumoniae inhibits acquisition of nonvaccine-type pneumococci, and may depend negatively on the inhibition of vaccine-type pneumococci by nonvaccine-type pneumococci. We used a mouse model of intranasal carriage of pneumococci to test whether such inhibition occurs between different pneumococcal strains. Mice carrying a streptomycin-resistant derivative of S. pneumoniae BG9163 (serotype 6B) as a resident strain showed reduced levels of colonization when challenged intranasally by optochin-resistant derivatives of the same strain and of a serotype 23F pneumococcus, BG8826. Inhibition could be overcome by increasing the dose of the challenge strain. Carriage of optochin-resistant BG9163 did not inhibit acquisition of the streptomycin-resistant variant. Colonization by a challenge strain did not significantly affect the level of colonization with the resident strain. These results provide evidence that is consistent with several hitherto untested assumptions of mathematical models of serotype replacement and suggest that a biological mechanism exists that could account for serotype replacement that is observed in clinical trials. The findings provide a basis for further studies of in vivo interactions between strains of S. pneumoniae.


Asunto(s)
Antibiosis/inmunología , Mucosa Nasal/inmunología , Mucosa Nasal/microbiología , Streptococcus pneumoniae/crecimiento & desarrollo , Streptococcus pneumoniae/inmunología , Animales , Vacunas Bacterianas/inmunología , Recuento de Colonia Microbiana , Femenino , Ratones , Ratones Endogámicos C57BL , Modelos Inmunológicos , Infecciones Neumocócicas/inmunología , Infecciones Neumocócicas/microbiología
2.
J Infect Dis ; 180(1): 133-40, 1999 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-10353871

RESUMEN

An infant mouse assay system for assessment of protective concentrations of human serum pneumococcal anticapsular antibodies is described. Passive immunization of anticapsular antibodies was evaluated for protection of infant mice challenged with Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 18C, and 23A, with bacteremia as an end point. Protection was defined as no detectable bacteremia in 70% of mice 48 h after challenge. Type-specific anticapsular concentrations required for protection varied with serotype (0.4 microg/mL). Across serotypes, there was no significant correlation between human IgG concentration in mouse serum and protection from bacteremia or between IgG concentration and opsonophagocytic titer. Significant correlation (r=.84, P<.001) was observed between opsonophagocytic titer of human IgG antibody in mouse sera and protection from bacteremia. Thus, protective concentrations of anticapsular antibodies against bacteremia are serotype dependent. Opsonophagocytosis is a better predictor of in vivo protective capacity of pneumococcal anticapsular antibodies than are ELISA IgG antibody concentrations.


Asunto(s)
Anticuerpos Antibacterianos/sangre , Cápsulas Bacterianas/inmunología , Bioensayo/métodos , Inmunización Pasiva , Streptococcus pneumoniae/inmunología , Animales , Animales Recién Nacidos , Bacteriemia , Humanos , Ratones , Proteínas Opsoninas , Fagocitosis , Streptococcus pneumoniae/patogenicidad
3.
Infect Immun ; 66(6): 2453-9, 1998 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-9596702

RESUMEN

Neisseria meningitidis serogroup C bactericidal titers and class-specific enzyme-linked immunosorbent assay (ELISA) antibody concentrations were measured in sera from 173 children (1 to 5 years old) before and 6 weeks and 7 months following vaccination with a quadrivalent (A/C/Y/W-135) polysaccharide vaccine. The immune responses of the children were compared with those of 40 adults 6 weeks postvaccination. Both bactericidal titers and ELISA antibody concentrations were significantly higher in the adults than in the children (P < 0.05). In addition, the ratio of immunoglobulin G (IgG) to IgM was higher in the children than in the adults. With an ELISA total antibody concentration of >/=2 microg/ml used as a measure of seroconversion, >/=84% of the individuals from each age group responded to the serogroup C polysaccharide. However, with a >/=4-fold-increase in bactericidal titer used, only 18% of 1-year-olds, 32% of 2-year-olds, and 50 to 60% of 3-, 4-, and 5-year-olds seroconverted. The ELISA results suggest that >50% of all children retained >/=2 microg of total antibody per ml at 7 months postimmunization. However, the bactericidal titers suggest that <10% of children <4 years old retained a >/=4-fold increase at 7 months following vaccination. Of particular note, 59 of 79 sera (75%) from the 1- and 2-year-olds had high ELISA antibody concentrations (2 to 20 microg/ml) with no associated bactericidal titer (<1:8). Discordant results between bactericidal titers and ELISA antibody concentrations were not explained by the presence of IgA blocking antibody or relative levels of IgG and IgM. The bactericidal results show age-dependent differences in the production and retention of antibody in young children immunized with serogroup C polysaccharide; these differences are not evident with the ELISA data.


Asunto(s)
Anticuerpos Antibacterianos/sangre , Vacunas Bacterianas/uso terapéutico , Infecciones Meningocócicas/prevención & control , Polisacáridos Bacterianos/uso terapéutico , Vacunación , Adulto , Factores de Edad , Especificidad de Anticuerpos , Vacunas Bacterianas/inmunología , Niño , Preescolar , Ensayo de Inmunoadsorción Enzimática , Humanos , Técnicas Inmunológicas , Lactante , Infecciones Meningocócicas/clasificación , Infecciones Meningocócicas/inmunología , Montana , Polisacáridos Bacterianos/inmunología , Serotipificación
4.
Clin Diagn Lab Immunol ; 4(2): 156-67, 1997 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-9067649

RESUMEN

A standardized serum bactericidal assay (SBA) is required to evaluate the functional activity of antibody produced in response to Neisseria meningitidis serogroup A and C vaccines. We evaluated assay parameters (assay buffer, target strains, growth of target cells, target cell number, complement source and concentration, and methods for growth of surviving bacteria) which may affect the reproducibility of SBA titers. The various assay parameters and specificity of anticapsular antibody to five serogroup A strains (A1, ATCC 13077, F8238, F9205, and F7485) and four serogroup C strains (C11, G7880, G8050, and 1002-90) were evaluated with Centers for Disease Control and Prevention meningococcal quality control sera. The critical assay parameters for the reproducible measurement of SBA titers were found to include the target strain, assay incubation time, and complement. The resulting standardized SBA was used by 10 laboratories to measure functional anticapsular antibody against serogroup A strains F8238 and serogroup C strain C11. In the multilaboratory study, SBA titers were measured in duplicate for 14 pairs of sera (seven adults and seven children) before and after immunization with a quadrivalent polysaccharide (A, C, Y, and W-135) vaccine. The standardized SBA was reliable in all laboratories regardless of experience in performing SBAs. For most sera, intralaboratory reproducibility was +/- 1 dilution; interlaboratory reproducibility was +/- 2 dilutions. The correlation between median titers (interlaboratory) and enzyme-linked immunosorbent assay total antibody concentrations was high for both serogroup A (r = 0.86; P < 0.001; slope = 0.5) and serogroup C (n = 0.86; P < 0.001; slope = 0.7). The specified assay, which includes the critical parameters of target strain, incubation time, and complement source, will facilitate interlaboratory comparisons of the functional antibody produced in response to current or developing serogroup A and C meningococcal vaccines.


Asunto(s)
Actividad Bactericida de la Sangre/inmunología , Neisseria meningitidis/inmunología , Adulto , Anticuerpos Antibacterianos/sangre , Vacunas Bacterianas/inmunología , Preescolar , Proteínas del Sistema Complemento/inmunología , Humanos , Técnicas de Inmunoadsorción , Lactante , Laboratorios , Infecciones Meningocócicas/inmunología , Infecciones Meningocócicas/prevención & control , Persona de Mediana Edad , Neisseria meningitidis/clasificación , Estándares de Referencia , Reproducibilidad de los Resultados , Serotipificación , Especificidad de la Especie
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA